| Literature DB >> 26955891 |
Changsong Wang1,2, Xiaoyang Wang1,3, Chunjie Chi1, Libo Guo1, Lei Guo1, Nana Zhao1, Weiwei Wang1, Xin Pi1, Bo Sun1, Ailing Lian1, Jinghui Shi1, Enyou Li1.
Abstract
To identify the best lung ventilation strategy for acute respiratory distress syndrome (ARDS), we performed a network meta-analysis. The Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, CINAHL, and the Web of Science were searched, and 36 eligible articles were included. Compared with higher tidal volumes with FiO2-guided lower positive end-expiratory pressure [PEEP], the hazard ratios (HRs) for mortality were 0.624 (95% confidence interval (CI) 0.419-0.98) for lower tidal volumes with FiO2-guided lower PEEP and prone positioning and 0.572 (0.34-0.968) for pressure-controlled ventilation with FiO2-guided lower PEEP. Lower tidal volumes with FiO2-guided higher PEEP and prone positioning had the greatest potential to reduce mortality, and the possibility of receiving the first ranking was 61.6%. Permissive hypercapnia, recruitment maneuver, and low airway pressures were most likely to be the worst in terms of all-cause mortality. Compared with higher tidal volumes with FiO2-guided lower PEEP, pressure-controlled ventilation with FiO2-guided lower PEEP and lower tidal volumes with FiO2-guided lower PEEP and prone positioning ventilation are associated with lower mortality in ARDS patients. Lower tidal volumes with FiO2-guided higher PEEP and prone positioning ventilation and lower tidal volumes with pressure-volume (P-V) static curve-guided individual PEEP are potential optimal strategies for ARDS patients.Entities:
Mesh:
Year: 2016 PMID: 26955891 PMCID: PMC4783789 DOI: 10.1038/srep22855
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Twenty-six ventilation strategies for ARDS.
| A | LVT + PV-HPEEP | lower tidal volumes with P-V static curve-guided higher PEEP |
|---|---|---|
| B | HVT + FiO2-LPEEP | higher tidal volumes with FiO2-guided lower PEEP |
| C | LVT + FiO2-LPEEP + HFOV + prone | lower tidal volumes with FiO2-guided lower PEEP and high-frequency oscillatory ventilation following prone positioning |
| D | HVT + HDPLV | higher tidal volumes with higher dose partial liquid ventilation |
| E | LVT + FiO2-LPEEP | lower tidal volumes with FiO2-guided lower PEEP |
| F | PCV + FiO2-LPEEP | pressure controlled ventilation with FiO2-guided lower PEEP |
| G | HVT + FiO2-LPEEP + prone | higher tidal volumes with FiO2-guided lower PEEP and prone positioning |
| H | LVT + FiO2-HPEEP | lower tidal volumes with FiO2-guided higher PEEP |
| I | LVT + FiO2-HPEEP + LDPLV | lower tidal volumes with FiO2-guided higher PEEP and lower dose partial liquid ventilation |
| J | LVT + FiO2-HPEEP + HDPLV | lower tidal volumes with FiO2-guided higher PEEP and higher dose partial liquid ventilation |
| K | PV-PEEP and VT + RM | static pressure-volume (P-V) curve was measured daily, PEEP and VT were set based on P-V variation. and the open-lung potential was evaluated before recruitment maneuvers |
| L | BiPAP + RM | BiPAP mechanical ventilation combined with lung recruitment maneuvers |
| M | PC SIMV + FiO2-LPEEP | pressure-controlled SIMV (synchronized intermittent ventilation)-mode with pressure support and FiO2-guided lower PEEP |
| N | LVT + esophageal pressure- PEEP | lower tidal volumes with esophageal-pressure guided PEEP |
| O | PC SIMV + PV-HPEEP | pressure-controlled SIMV (synchronized intermittent ventilation)-mode with pressure support and P-V static curve-guided higher PEEP |
| P | LVT + FiO2-LPEEP + RM | lower tidal volumes with FiO2-guided lower PEEP and lung recruitment maneuvers |
| Q | permissive hypercapnia + RM + LAP | permissive hypercapnia, recruitment maneuvers and low airway pressures |
| R | APRV | airway pressure release ventilation |
| S | HFOV | high-frequency oscillatory ventilation |
| T | LVT + PV individual PEEP | lower tidal volumes with P-V static curve-guided individual PEEP |
| U | LVT + FiO2-HPEEP | lower tidal volumes with FiO2-guided higher PEEP and extracorporeal CO2 elimination |
| V | ASV | Adaptive support ventilation |
| W | LVT + FiO2-HPEEP + PRONE | lower tidal volumes with FiO2-guided higher PEEP and prone positioning |
| X | LVT + FiO2-LPEEP + PRONE | lower tidal volumes with FiO2-guided lower PEEP and prone positioning |
| Y | LVT + ARM | lower tidal volumes with PEEP titration after an alveolar recruitment maneuver (ARM) |
| Z | HFOV + RM | high-frequency oscillatory ventilation with tracheal gas insufflation and recruitment maneuver |
Abbreviations: ARDS, Acute Respiratory Distress Syndrome; PEEP, Positive End-expiratory Pressure.
Figure 1Flow diagram of the literature search.
Characteristics of randomized controlled trials of twenty-six ventilation strategies for ARDS.
| Source | Ventilation strategies | Jadadscale | No. of Patients | Age(y)Mean ± SD | Oxygenation index(mmHg) Mean ± SD | Diagnosis | Result | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mortality | Length ofmechanical ventilation (d) Mean ± SD | ICU length of stay (d) Mean ± SD | Barotrauma(n) | Hospital Lengthof stay (d)Mean ± SD | |||||||
| Amato | HVT + FiO2−LPEEP vs. HVT + FiO2−LPEEP | 6 | 53 | 33 ± 13/36 ± 14 | 112/134 | ARDS | Not reported | Not reported | 2/10 | Not reported | |
| Death in the ICU | |||||||||||
| Mortality at 28 days | |||||||||||
| Brochard | LVT + FiO2−LPEEP vs. HVT + FiO2−LPEEP | 6 | 116 | 57.0 ± 15.3/56.5 ± 15.3 | 144/155 | ARDS | 23.1 ± 20.2/21.4 ± 16.3 | 33.5 ± 28.7/29.7 ± 19.4 | Not reported | Not reported | |
| Confalonieri | LVT + FiO2−LPEEP vs. HVT + FiO2−LPEEP | 6 | 52 | 49.8/46.9 | 150 ± 69/128 ± 51 | ARDS | Not reported | Not reported | 2/1 | Not reported | |
| Esteban | LVT + FiO2−LPEEP vs. PCV + FiO2−LPEEP | 7 | 79 | 59 ± 16/56 ± 17 | 131 ± 48/126 ± 47 | ARDS | Not reported | 25 ± 19/21 ± 15 | 4/6 | 30 ± 24/27 ± 20 | |
| Death in the ICU | |||||||||||
| ARDSnetwork | LVT + FiO2−LPEEP vs. HVT + FiO2−LPEEP | 6 | 861 | 51 ± 17/52 ± 18 | 138 ± 64/134 ± 58 | ARDS | 12 ± 11/10 ± 11 | Not reported | 43/47 | Not reported | |
| Gattinoni | HVT + FiO2−LPEEP vs. HVT + FiO2−LPEEP + prone | 5 | 304 | 57 ± 16/59 ± 17 | 129.5 ± 47.5/125.3 ± 48.8 | ARDS | Not reported | Not reported | Not reported | Not reported | |
| Kacmarek | LVT + FiO2−HPEEP vs. LVT + FiO2−HPEEP + LDPLV vs. LVT + FiO2−HPEEP + HDPLV | 7 | 311 | 46 ± 12/45 ± 14/45 ± 13 | 147 ± 54/137 ± 58/143 ± 52 | ARDS | 13.0 ± 9.3/7.4 ± 8.5/9.9 ± 9.1 | Not reported | 3/8/13 | Not reported | |
| Long | LVT + FiO2−HPEEP vs. PV−PEEP and VT + RM | 4 | 30 | 61 ± 16/58 ± 18 | 142 ± 34/120 ± 29 | ARDS | 4(1–8)/11(5–8)b | 3(0–8)/ 11(5–16)b | 2/0 | Not reported | |
| Wang | BiPAP + RM vs. LVT + FiO2−LPEEP | 4 | 28 | 36 ± 8/38 ± 9 | 180 ± 10/179 ± 9 | ARDS | 14 ± 3/19 ± 3 | Not reported | 1/1 | Not reported | |
| Didier | LVT + FiO2−LPEEP + PRONEvs. HFOV vs. LVT + FiO2−LPEEP + HFOV + prone | 4 | 43 | 52 ± 13/45 ± 14/56 ± 17 | 122 ± 28 | ARDS | Not reported | Not reported | Not reported | Not reported | |
| Xi | LVT + FiO2−LPEEP + RM vs. LVT + FiO2−LPEEP | 6 | 110 | 62.2 ± 16.0/65.5 ± 15.2 | 93.8 (68.7–150.0)/120.0 (88.3–140.0) | ARDS | 10.8 ± 10.1/10.8 ± 10.1 | 22.5 ± 22.2/19.8 ± 24.8 | Not reported | 43.2 ± 45.6/33.2 ± 34.0 | |
| Mortality at 28 days | |||||||||||
| Death in ICU | |||||||||||
| Hodgson | permissive hypercapnia + RM + LAP vs. LVT + FiO2−LPEEP | 7 | 20 | 60 ± 5/58 ± 4 | 155/149 | ARDS | 180(87–298)/341(131–351) | 9.9 (5.6–14.8)/16.0 (8.1–19.3) | Not reported | 17.9 (13.7–34.5)/24.7 (20.5–39.8)b | |
| Dolinay | APRV vs. LVT + FiO2−LPEEP | 4 | 34 | Not reported | Not reported | ARDS | 6.4/7.7 | Not reported | Not reported | 8.6/10.3a | |
| Death in ICU | |||||||||||
| Young | HFOV vs. LVT + FiO2−LPEEP | 5 | 795 | 55.4 ± 16.2 | 113 ± 38/113 ± 37 | ARDS | Mortality at 30 days | Not reported | 17.6 ± 16.6/16.1 ± 15.2 | Not reported | 33.9 ± 41.6/33.1 ± 44.3 |
| Death in ICU | |||||||||||
| Ferguson | HFOV vs. LVT + FiO2−HPEEP | 5 | 548 | 55 ± 16/54 ± 16 | 121 ± 46/114 ± 38 | ARDS | 11(7–19)/10(6–18) | Not reported | 46/34 | 30(16–45)/25(15–41)b | |
| Death in ICU | |||||||||||
| Mortality at 28 days | |||||||||||
| Pintado | LVT + PV individual PEEP vs. LVT + FiO2−LPEEP | 5 | 70 | 55.6 ± 3.1 | 133.15 ± 5.88/146.33 ± 6.19 | ARDS | Not reported | 21 (15–46)/20 (12–29) | 6/6 | 55 ± 7/32 ± 3 | |
| Bein | LVT + FiO2−HPEEP vs. LVT + FiO2−HPEEP | 5 | 79 | 49.8 ± 12/48.7 ± 17 | 152 ± 37/168 ± 37 | ARDS | Not reported | 31.3 ± 23/22.9 ± 11 | Not reported | 46.7 ± 33/35.1 ± 17 | |
| Rappaport | HVT + FiO2−LPEEP vs. PCV + FiO2−LPEEP | 6 | 27 | 51.6 ± 6.3/43.1 ± 4.3 | 77.5 ± 9.85/74.4 ± 6.54 | ARDS | Not reported | Not reported | 1/0 | Not reported | |
| Hirschl | HVT + HDPLV vs. HVT + FiO2−LPEEP | 6 | 90 | 44 ± 2/41 ± 3 | 178 ± 12/198 ± 22 | ARDS | 6.3 ± 1/6.7 ± 1.8 | Not reported | 15/5 | Not reported | |
| Varpula | APRV vs. PC SIMV + PV-HPEEP | 4 | 58 | 50.0 (38.5–60.5)/44.0(35.5–53.0) | 150.0 ± 10.5/164.3 ± 10.5 | ARDS | Mortality at day 28 | 13.4 ± 1.7/12.2 ± 1.5 | 11.9 ± 1.7/10.7 ± 1.4 | Not reported | Not reported |
| Roy | LVT + FiO2−LPEEP vs. LVT + FiO2−HPEEP | 7 | 549 | 49 ± 17/54 ± 17 | 165 ± 77/151 ± 67 | ARDS | Not reported | Not reported | 27/30 | Not reported | |
| CHEN | PCV + FiO2−LPEEP vs. HVT + FiO2-LPEEP | 4 | 56 | 16–68/18–65 | < 200 | ARDS | Not reported | Not reported | Not reported | 2/8 | Not reported |
| Taccone | LVT + FiO2−LPEEP + PRONE vs. LVT + FiO2−LPEEP | 7 | 342 | 60/61a | 141/77 | ARDS | Mortality at day 28 | 25(12–28)/19(9–28) | 17.5(9–31)/16(8–26) | Not reported | Not reported |
| Death in ICU | |||||||||||
| Varpula | APRV vs. PC SIMV + PV-HPEEP | 4 | 37 | Not reported | 158/65 | ARDS | Not reported | Not reported | Not reported | Not reported | |
| Agarwal | LVT + FiO2−LPEEP vs. ASV | 7 | 48 | 29.7 ± 11.6/31.4 ± 14.9 | 96.6 ± 34.5/107.3 ± 41.9 | ARDS | 6 (3.5–11.5)/5(3–11) | 9 (4.5–15.5)/8(6–14) | Not reported | 11 (6.5–18.5)/11 (8–16) | |
| Derdak | HFOV vs. LVT + FiO2−HPEEP | 7 | 148 | 48 ± 17/51 ± 18 | 114 ± 37/111 ± 42 | ARDS | Mortality at 30 days | 22 ± 21/20 ± 31 | Not reported | 7/9 | Not reported |
| Bollen | HFOV vs. LVT + FiO2−HPEEP | 7 | 61 | 81.0 ± 20.5/81.7 ± 12.5 | < 200 | ARDS | 20 ± 6/18 ± 5 | Not reported | 1/1 | Not reported | |
| Villar | LVT + PV-HPEEP vs. HVT + FiO2−LPEEP | 7 | 95 | 48(28–62)/52(40–69) | 124 ± 54/139 ± 43 | ARDS | Death in ICU | 10.9 ± 9.4/6.0 ± 7.9 | Not reported | 2/4 | Not reported |
| Voggenreiter | LVT + FiO2−HPEEP + PRONE vs. LVT + FiO2−HPEEP | 5 | 40 ± 14/43 ± 10 | 215 ± 63/228 ± 75 | ARDS | 30 ± 17/33 ± 23 | Not reported | Not reported | Not reported | ||
| Mercat | LVT + PV-HPEEP vs. LVT + FiO2−LPEEP | 5 | 767 | 60 ± 16/60 ± 15 | 143 ± 57/144 ± 58 | ARDS | 7(0.0–19)/3 (0.0–17) | Not reported | 26/22 | Not reported | |
| Mortality at 28 days | |||||||||||
| Mortality at 60 days | |||||||||||
| Guérin | LVT + FiO2−LPEEP + PRONE vs. LVT + FiO2−LPEEP | 5 | 466 | 58 ± 16/60 ± 16 | 100 ± 20/100 ± 30 | ARDS | Mortality at 28 days | 17 ± 16/19 ± 21 | 24 ± 22/26 ± 27 | 15/13 | Not reported |
| Fernandez | LVT + FiO2−LPEEP + PRONE vs. LVT + FiO2−LPEEP | 5 | 40 | 53.9 ± 17.9/55.3 ± 14.6 | 157.8 ± 83.8/153.2 ± 59.4 | ARDS | 11.9 ± 9.2/15.7 ± 16.9 | 14.7 ± 9.7/17.5 ± 16.1 | 0/1 | 31.3 ± 26.4/25.5 ± 17.4 | |
| Huh | LVT + ARM vs. LVT + FiO2−LPEEP | 4 | 57 | 55.0 ± 3.7/62.0 ± 2.2 | 110.8 ± 6.3/ 115.0 ± 8.5 | ARDS | 19.8 ± 0.5/15.2 ± 3.2 | 25.1 ± 5.6/21.4 ± 5.3 | 3/3 | Not reported | |
| Mortality at 28 days | |||||||||||
| Death in ICU | |||||||||||
| Mentzelopoulos | HFOV + RM vs. LVT + FiO2−LPEEP | 7 | 125 | 50.7 ± 17.7/52.9 ± 17.1 | 96.5 ± 31.3/106.9 ± 27.7 | ARDS | Not reported | 31.9 ± 23.4/37.4 ± 19.6 | Yes | 52.8 ± 30.6/64.2 ± 27.8 | |
| Sun | PC SIMV + FiO2−LPEEP vs. LVT + FiO2−LPEEP | 4 | 85 | 50 ± 17/51 ± 8 | ≤ 300 | ARDS | 8.4 ± 2.1/10.7 ± 1.2 | 10.2 ± 2.2/13.7 ± 3.1 | Not reported | Not reported | |
| Talmor | LVT + esophageal pressure-PEEP vs. LVT + FiO2−LPEEP | 6 | 61 | 54.5 ± 16.1/51.2 ± 23.0 | 147 ± 56/145 ± 57 | ARDS | 12.0(7.0–27.5)/16.0(7.0–20.0) | 15.5(10.8–28.5)/13.0(7.0–22.0) | 0/0 | Not reported | |
| Mortality at 28 days | |||||||||||
(Regimens are described in Table 3).
*primary outcomes for overall survival.
amean.
bmedian (interquartile range).
crange.
dmean (interquartile range). Abbreviations: ARDS, Acute Respiratory Distress Syndrome; ICU, Intensive Care Unit. Reference to ARDS Clinical Trials Network (37), ARDS Network (4) and Taccone’s (31) method, based on the primary study, high PEEP was defined by PEEP < 10 cm H2O, low tidal volume was defined by VT < 8 mL/kg.
Figure 2Network of the comparisons for the Bayesian network meta-analysis.
The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments.
Figure 3Hazard ratios for death in the Bayesian network meta-analysis versus B.
CI = credible interval for Bayesian network meta-analysis. Hazard ratios (HRs) estimated from random effects, Bayesian network meta-analysis. *95% CI does not contain 1.
Pooled hazard ratios for death and pooled odds ratios for the incidence of barotraumas.
Hazard ratios for death are above the diagonal line (row defining treatment vs. column defining treatment), while odds ratios for the incidence of barotraumas are below the diagonal line (column defining treatment vs. row defining treatment). If the range of the 95% CI for HR and OR does not contain 1, the red numbers indicate corresponding values. … = not compared; CI = credible interval; HR = hazard ratio; OR = odds ratios.
Figure 4Ranking of treatments in terms of all-cause mortality benefit and incidence of barotraumas.
The probability ranking represents only a possibility without certainty; combining the direct and indirect evidence analysis on overall mortality has more reference significance.